

SPHERIX INC  
Form 8-K  
March 15, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **March 15, 2012**

**Spherix Incorporated**

(Exact name of registrant as specified in its charter)

(State or other jurisdiction  
of incorporation)

**Delaware**

(Commission  
File Number)

**0-5576**

(I.R.S. Employer  
Identification No.)

**52-0849320**

(Address of principal executive offices)

**6430 Rockledge Drive, Suite 503, Bethesda, Maryland**

(Zip Code)

**20817**

Registrant's telephone number, including area code **301-897-2540**

(Former name or former address, if changed since last report.)

## Edgar Filing: SPHERIX INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure.**

Dr. Robert Lodder, Company President, will present Measurement of Lipoproteins in Treatment with SPX-106, at the Pittcon Conference in Room 308C of the Orlando Convention Center, Orlando, FL, at 10:15 a.m. on March 15, 2012. The presentation is available on the Company's website at [www.spherix.com](http://www.spherix.com), is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

**Section 9 Financial Statements and Exhibits**

Item 9.01 Financial Statements and Exhibits

Exhibits

99.1 Spherix Incorporated Presentation, Measurement of Lipoproteins in Treatment with SPX-106, March 15, 2012

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Spherix Incorporated  
(Registrant)

**By:**

/s/ Robert L. Clayton  
Robert L. Clayton  
CFO

Date: March 15, 2012